Álvarez-Román, M. T., Cuervo-Arango, I., Pérez-Santamarina, R., Poveda, J. L., Romero, J. A., Santamaría, A., Trillo-Mata, J. L., Tort, M., & Badia, X. (2019). Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis. Global and Regional Health Technology Assessment, 6(1). https://doi.org/10.33393/grhta.2019.452